Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

AM Rx vs NuBloom

AM Rx
Graded #491

Lower grade

vs+19.4
NuBloom
Graded #137

Higher grade

The verdict

NuBloom takes it — 69/100 to 49.6/100.

NuBloom grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NuBloom is a women's metabolic-health telehealth practice founded by family and integrative-medicine physician Dr.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueNuBloom +22
50
72
Dose & formulationAM Rx +11
65
54
Clinical oversightNuBloom +41
41
82
Labs & monitoringNuBloom +12
49
61
FulfillmentNuBloom +27
58
85
Contract termsNuBloom +35
20
55
AM Rx · left barNuBloom · right bar

The numbers

MetricAM RxNuBloom
WeighScore49.6/10069/100
GradeCC
Scorecard rank#491#137
Semaglutide$151/mo (quarterly plan, plus a separate fee, compounded)$149/mo (2.4 mg dose, compounded)
TirzepatideNot disclosed$279/mo (15 mg dose, compounded)
CoverageCoverage not published49 states
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
AM Rx

Graded #491 · C

Strengths

  • Insurance coordination for brand-name GLP-1s — as low as $25/mo
  • All four major brand-name GLP-1s available (Ozempic, Wegovy, Zepbound, Mounjaro)
  • HSA and FSA accepted
  • Video visits available with providers averaging 10+ years' experience
  • Compounded semaglutide from $151/mo on the quarterly plan

Where it loses points

  • Active FTC/DOJ lawsuit over deceptive billing and subscription practices
  • Novo Nordisk false-advertising lawsuit (Aug 2025)
  • Parent company Zealthy holds a BBB D- rating with 2,370+ complaints
  • Trustpilot 2.0/5, with 85% one-star reviews citing billing disputes and unreachable support
  • FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
NuBloom

Graded #137 · C

Strengths

  • Transparent, openly published pricing: compounded semaglutide $149/mo and tirzepatide $279/mo as flexible month-to-month subscriptions
  • Founded and medically led by a named physician (Dr. Marianne Pinkston Mueller, family/integrative medicine, 25+ years)
  • Whole-person model pairs GLP-1s with hormone, gut-health and longevity care plus in-depth lab testing
  • State coverage published openly: 49 states listed on the site (all except Mississippi)
  • Optional 90-day 1:1 coaching program with weekly meetings and unlimited text support ($599/mo)

Where it loses points

  • Compounding pharmacy partners are not named anywhere on the site — a transparency gap
  • NuBloom's own LegitScript/PCAB status is not displayed; only its telehealth partner is certified
  • Compounded medications are not FDA-approved; one FAQ loosely calls them 'FDA-approved,' contradicting the product pages
  • All sales are final and medical consult fees are non-refundable; no returns on prescription products
  • Disputes go to binding individual arbitration; the Terms' governing-law state is left as an unfilled '[STATE]' placeholder

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard